Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GX-G3
- Development stage
- Phase 2
- Lead developer
- Genexine
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
GX-G3 is a next-generation, long-acting granulocyte colony stimulating factor (G-CSF) fusion protein developed for the treatment of chemotherapy-induced neutropenia. It utilizes Genexine’s proprietary hybrid-Fc (hyFc) platform, which combines human IgD-Fc and IgG4-Fc domains to extend half-life and reduce immunogenicity by eliminating antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Compared to first-generation filgrastim and second-generation pegfilgrastim, GX-G3 demonstrates a longer elimination half-life and similar or improved efficacy in reducing the duration of severe neutropenia. The drug is administered as a single injection per chemotherapy cycle and has shown safety and tolerability comparable to existing therapies in clinical trials[1][2][5].
- Other names
- G-CSF-hyFc
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on GX-G3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GX-G3.